Industry analyst GlobalData says that the Chinese approval of Brii Biosciences’ (HKG: 2137) monoclonal antibody combo amubarvimab/romlusevimab will raise the country’s status as an R&D hub.
The decision makes Brii the first local firm to secure approval for a COVID-19 neutralizing antibody combination therapy.
AstraZeneca (LSE: AZN), which has pursued an aggressive growth strategy in China, is likely to be the only other developer with an option of this type under consideration in the country.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze